Personalized medicine in major depressive disorder -- opportunities and pitfalls

Details

• Personal Author:
  Miller DB ; O'Callaghan JP
• Description:
  The sequencing of the human genome in the early days of this millennium was greeted with great fanfare as this accomplishment was expected to revolutionize medicine and result in individualized treatments based on the genetic make-up of the patient. The ultimate promise of personalized medicine would be fulfilled with the identification of disease biomarkers that would be widely available for use in diagnosis and treatment. Progress, however, has been slow in providing disease biomarkers or approved diagnostic tests. This is true for major depressive disorder (MDD), despite its prevalence in the general population and the widespread acceptance of its biological basis. Studies using strategies like genome-wide association and candidate gene analyses have identified a number of possible biomarkers of MDD, including serum levels of neurotrophic factors, inflammatory cytokines and HPA axis hormones, but none have proven sufficiently powerful for clinical use. The lack of biologically based tests available for use in identifying patients with MDD is a significant impediment to personalized and more effective treatment, because it means diagnosis continues to be driven by subjective symptoms. While genetic studies of MDD have not yet led to diagnostic and treatment biomarkers, progress in determining the role of the genome in drug metabolism heralds the first effort in personalized prescribing for the antidepressants. The FDA suggested and approved genotyping tests for common variants of drug metabolism genes, such as the cytochrome p450s. By using these tests a physician can select an appropriate antidepressant for a given patient, as differences in clearance, half-life, and peak blood concentrations are controlled by genetic variability in drug metabolism. Personalization in drug choice can be achieved because these tests: (1) identify responders and non-responders; (2) provide alerts to possible adverse drug events; and (3) help optimize dose. Improved ways of diagnosing and prescribing effective treatments for MDD are needed, as the available methods are inadequate and symptom based. In the foreseeable future, further interrogation of the genome may serve as the basis for development of new personalized medicine strategies for diagnosis and treatment of MDD. [Description provided by NIOSH]
• Subjects:
  Biomarkers Diagnosis Energy Metabolism Genetics Men Occupational Health Safety Women
• Keywords:
  Author Keywords: Biomarkers Diagnostic-tests Genetic-factors Genome Humans Metabolism
• ISSN:
  0026-0495
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  OSHA Region 3 ; West Virginia
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  HELD - Health Effects Laboratory Division
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  62
• NIOSHTIC Number:
  nn:20041618
• Citation:
  Metab Clin Exp 2013 Jan; 62(S1):S34-S39
• Contact Point Address:
  Diane B. Miller, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV 26505
• Email:
  dum6@cdc.gov
• Federal Fiscal Year:
  2013
• NORA Priority Area:
  Public Safety
• Peer Reviewed:
  True
• Source Full Name:
  Metabolism: Clinical and Experimental
• Supplement:
  1
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:3a31cf237a1f4fbd9f82fc36950bbf096154ac588972216ef9613b3bea3405fdae9be8798bbf4cc1ef65661d76fd69fe9009c1b85b033960e140b51a2a97217f
• Download URL:
  https://stacks.cdc.gov/view/cdc/194128/cdc_194128_DS1.pdf
• File Type:
  [PDF - 188.54 KB ]